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Anaesthesia titles from Amold Publishers
Paediatric Anaesthesia 2/e
Eds: D J Hatch & E Sumner
The previous edition of this well-respected text was identified as the top
paediatric title in a listing of the best specialist text-books. In the new
edition, the editors bring together an experi-enced team of intemational
experts to share practical advice on the management of children and
babies needing anaesthesia. The emphasis is on commonly
encountered problems from everyday practice.
Oct 1999, c 512 pp, hard cover, Ri 050
Pain: Acute and Chronic 2/e
Edward A Shipton
The physician dealing with patients with acute, chronic or cancer pain needs
a concise, practical but comprehensive guide to best management prac-
tice. This introductory clinical textbook examines all aspects of the assess-
ment and management of pain at the basic level appropriate forthe generalist
physician requiring an overview of all aspects of pain, and pain control. It
covers the physiology, pathology and clinical manifestations of different types
of pain, and considers the physical, pharmacological and psychological in-
terventions required to treat, and rehabilitate, patients with pain. Other is-
sues include new modes of drug delivery, paediatric pain, AIDS-related pain,
fibromyalgia, and the issue of self-help in pain control.
August 1999, 416 pp, soft cover, R375
Principles of Physiology for Anaesthetists
lan Power and Peter Kam
The practise of anaesthesia, including intensive care medicine and pain
.management requires a considerable understanding of normal
physiology. This book has been written to explain the fundamentals of
physiology, using diagrams to aid understanding of difficult concepts.
There is a separate section on pain.
Dec 1999, c 352 pp, paperback, R399
Clinical Problems in Obstetric Anaesthesia
Eds: G Lyons and L F Russell
A comprehensive, up-to-date treatise which describes the various clinical
problems that the anaesthetist can face and outlines the best
management practice that can be adopted.
1997, 304 pp, hard cover, Ri 025
Short Practice of Anaesthesia
Eds: MMorgan and G Hall
Ideal for both trainee anaesthetists and as a ready reference for senior
practitioners, the emphasis is on day to day practice and important
clinical considerations in anaesthesia.
1997,856 pp, hard cover, Ri 280
Orders: The SA Medical Association, Private Bag Xi, Pinelands
7430. tel (021) 531-3081, tax: (021) 531-4126,
e-mail: jstrydom@samedical.org Prepayment is required by cheque,
Visa or MasterCard. Payment will not be taken until books are
despatched.





RP Clauss, W M Giildenpfennig, H W Nel, M M Sathekge,
R R Venkannagari
A young semi-eomatose male patient was investigated using
99mTc hexamethyl-propylene amine oxime (""""rc HMPAO)
brain single photon emission computed tomography (SPECf)
before and after administration of the gamma-aminobutyric
acid (GABA) agonist zolpidem. It was observed that 15
minutes after application of the drug the patient awoke from
his semi-eomatose condition and remained awake for the
next 3 - 4 hours. When drug action subsided he returned to
his semi-eomatose state. Brain SPECf before drug application
showed large hypo-active areas in certain parts of the brain.
Brain SPECf after drug application showed a generalised
cortical activation relative to the cerebellum and a marked
and amplified activation of the areas that were hypo-active
before drug application.
s AfT Med /2000; 90: 68-72.
A semi-conscious patient was examined using 99mTc
hexamethyl-propylene amine oxime (99mTc HMPAO) brain
single photon emission computed tomography (SPECT) before
and after application of the. anti-insomnia drug zolpidem.
Consciousness may be defined as the ability to respond to
sensory stimuli and to have subjective experiences. Impaired
consciousness can range from mild suppression of
consciousness to complete coma.' Coma is a state of
unconsciousness from which the patient cannot be aroused.'
99mTc HMPAO is a lipophylic amine that crosses the blood-
brain barrier and is used as a marker of brain perrusion and
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metabolism.' When used in brain SPECT it delineates the grey
matter of the brain. The cerebral hemispheres, cerebellum,
thalamus and basal ganglia are therefore identified and their
activity can be semi-quantified.
Zolpidem is a non-benzodiazepine agent belonging to the
imidazopyridine class and is chemically distinct from sedatives
such as barbiturates, antihistamines, benzodiazepines and
cyclopyrrolones. It has a selectivity for stimulating garnma-
aminobutyric acid (GABA) function and is used for the
treatment of insomnia. It has a short half-life of 2.4 hours, with
no active metabolite, and it does not accumulate with repeated
administration. The drug is oxidised and hydroxylated by the
liver to foJ.?l inactive metabolites that are eliminated primarily
through renal excretion!
CASE REPORT
Ten ~grams of zolpidem was administered to a 28-year-old
man who had been semi-comatose for 3 years following a
motor vehicle accident. He had been normal and healthy before
the accid~nt other than suffering from retinitis pigrnentosa
since childhood.
On arrival at the hospital the patient's pupils were of equal
size and reactive to light, but he was verbally unresponsive.
The limbs flexed to pain with increase in tone, there was no
evidence of meningeal irritation, and the cervical spine was
normal. There was a flexor plantar response. A non-contrast
computed tomography (CT) scan showed a small intra-cerebral
haemorrhage in the left lentiform nucleus and thalamus area.
Intra-ventricular blood was noted in the occipital horn of both
lateral ventricles. A hyper-dense lesion was noted in the
brainstern area in keeping with intracerebral haemorrhage in
the area of the cerebellar peduncles. Full blood count and
serum biochemistry were within normal limits. Epanutin,
intravenous (IV) fluids and analgesics were administered to the
patient. His mean arterial pressure was kept above 90 rnmHg
to assure good cerebral blood flow. On the second day
following admission an intra-cranial pressure monitor was
inserted, and the reading was 14mmHg. The pressure did not
rise above 15 rnmHg in the subsequent days. The patient's
temperature was kept below 37.5°C.
On neurological assessment at the time of hospital discharge
the patient could open his eyes spontaneously. There was still
no verbal response and the best motor response was flexion
\'\ithdrawal on pain stimulus. He had right hemiplegia and a
significant spasticity in both upper and lower limbs, with
increased tone and reflexes. There was an asymptomatic
posture owing to the right hemiplegia. The recommended
treatment at the time of discharge from hospital was phenytoin
300 mg at night, enoxaparin 40 mg daily and paracetamol
6-hourly. The patient was admitted to a special home.
The abovementioned drugs were discontinued after some
time in the special home. In the subsequent months and years
the patient developed fixed flexion contractures of his right
arm and leg. Plantar flexion and an inversion contracture
occurred in his left foot and there was shortening of his flexor
and extensor hip muscles. He had hyperaesthesia (touch
defensiveness), was generally restless and had developed
chorea-type movements on the left side of his body. He could
not feed himself and had no sphincter control. His mental state
could be described as semi-comatose. He could open his eyes
spontaneously but did not respond to speech or other stimuli.
There was no verbal response to commands or questions. Since
there was no evidence of cognitive skills, memory or reasoning,
problem solving could not be tested. His emotional state could
also not be determined. The maximum score on the Glasgow
coma scale was 9/15.
In January 1999 the patient appeared extremely restless and
10 mg of zolpidem was prescribed to calm him. This drug was
chosen because of its limited vascular and cerebral side-effects
when compared with other insomnia medication. The patient
regained consciousness 15 minutes after ingestion of the drug
and greeted his mother for the first time in 3 years. It was the
first time in over 2 years that he had uttered a sound.
Zolpidem was administered on the subsequent mornings.
The patient regained consciousness for the duration of drug
action, whereafter he relapsed into a semi-comatose state
during the afternoon and night. After administering the drug
there was initially a slight cough, followed by an improvement
in skin colour. His eyes looked more awake and his upper lip
became firm. He Sighed and talked soon after these changes.
In his conscious phase the patient interacted spontaneously
and responded to simple questions related to the environment
and his relatives, providing short, appropriate answers. His
cognition appeared to be intact, and he could perform simple
calculations and write words dictated to him. The
hyperaesthesia and spasticity decreased. He was able to pick
up food and put it into his mouth. Eye opening was
spontaneous and appropriate. Although he sometimes forgot
time and place after being told, h.e did not appear confused.
His immediate and remote memory were good. His emotional
state was appropriate and his higher functions adequate, but
he was still restricted by his physical disabilities.
Since his periodic regaining of consciousness some months
ago, the patient has undergone an electro-encephalogram
(EEG) study, a full biochemical assessment, and repeat CT scan.
Biochemical investigations were normal and the brain
pathology; as seen on the CT scan, remained unchanged. The
most prominent change on an 8-channel EEG was the blocking
of an underlying posterior 10 Hertz (Hz) activity when the
patient opened his eyes after administration of zolpidem.
Before administration of zolpidem posterior activity did not
respond to eye opening. The patient was referred for a 99mTc
HMPAO brain SPECT study.
ORIGINAL ARTICLES
METHOD
Two brain SPECT studies were completed on different days.
The first study was completed during the semi-comatose state
and the second study was performed 1 hour after application
of 10 mg zolpidem (it had been noted that the patient's
maximum arousal was 1 hour after drug application). The 99mTc
HMPAO was prepared according to recommended protocolsY
Acquisitions were completed 30 minutes after intravenous
injection of 900 MBq 99mTc HMPAO, using a dual-head SOPHY
DST XLi gamma camera. Acquisition parameters were 64
angular views over 3600 at 45 seconds per view. Ultra-high
resolution fanbeam collimation without zoom was used and a
20% symmetrical window over 140 kiloelectron-volts (keV).
The images were reconstructed using a Metz pre-filter.
Transaxial, sagittal and coronal slices were constructed without
attenuation or scatter correction. The images before and after
application of zolpidem were compared visually and semi-
quantitatively by three experienced independent observers.
Semi-quantification involved a left/right comparison of activity
in comparative transaxial slices as well as between different
segments of the brain.
RESULTS
The transaxial and three-dimensional images of the patient's
brain before and after drug application are presented in Fig. 1.
There is a generalised increased tracer uptake by the cerebrum
relative to the cerebellum after drug administration. This may
be due either to decreased cerebellar activity or increased
cerebral activity.
The left occipital, parietal and posterior frontal lobe was
10 - 25% less active than the right in the semi-comatose state;
this improved in most parts to approximately 5% difference
after application of zolpidem (Fig. 2). The left temporal lobe
was hypo-active before the medication when compared with
the contralateral side, and had a very similar activity after the
medication. The left nucleus lentiformis area was hypo-active
before medication. The difference in activity between the left
and right lentiform nuclei was more than 20%. This difference
improved to less than 5% after application of the drug (Fig. 3).
Activity in the anterior frontal lobes was equal before
medication but the left anterior frontal lobe became more
prominent than the right after medication.
DISCUSSION
Since the first application of the zolpidem the patient has
shown progress in his emotional responses and
communication. However, when the medication stops working
the patient returns to his semi-comatose state. This case clearly
documents clinical and objective physiological changes as seen
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Fig. 1. Three-dimensional (a) and transaxial (b) images before and
after application of zolpidem.
. Fig. 2. Sagittal section through the right brain showing the difference
ofactivity between the cerebellUl7z and the cerebrum before and after
medication (a), and through the left frontal and parietal lobe before
and after medication (b).
-
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Fig. 3. Changes in the basal ganglia before and after medication (C =
caudate nucleus, L = lentiform nucleus, T = thalamus).
on 99mTc HMPAO SPECT after medication. As far as we know
this has not been described before.
Zolpidem is a preferential {Ol and to a lesser extent ffi:z
receptor agonist.7.SThese {Ol and ffi:z receptors interact
allosterically with the GABA-binding site; and increase
chloride influx by means of GABA-independent mechanisms.
GABA increases the permeability of post-synaptic membranes
to potassium. Hence it drives the membrane potential away
from the threshold for triggering the action potential, and in
this way acts as an inhibitory neurotransmitter. GABA is
formed by the decarboxylation of glutamate, a reaction
catalysed by glutamate decarboxylase. It is inactivated by
transamination to succinate semialdehyde, which is then
oxydised to form succinate. to
GABA receptors are found all over the brain. Animal studies
have sho\'lI1 that very high densities of {Ol and ffi:z receptors
occur in lamina N of the neocortex, substantia inominata and
in the molecular layer of the dentate gyrus. ~ receptor sites
predominate in lamina N of the sensorimotor cortical regions
and in the extrapyramidal motor system (globus pallidus,
ventral thalamic complex, subthalamic nucleus, substantia
nigra and cerebellum)."
It has been reported that catatonic patients may benefit from
zolpidem.12·!4 In one study, 7 out of 10 catatonic patients
experienced a decrease in their catatonic symptoms 10 - 15
minutes after drug administration. This effect lasted 3 - 4
hours.!' The drug also reduced agitation in patients with
Alzheimer's disease.!'
In a study of 10 patients with Parkinson's disease, it was
found that there was an improvement in rigidity, akinesia,
bradykinesia, posture and gait 45 - 60 minutes after zolpidem
administration. The effect lasted for 3 - 4 hours.!' Our patient
showed decreased rigidity after drug intake.
The changes investigated in the above studies followed
administration of 10 mg zolpidem. However, it has been
postulated that a lesser dose may achieve a similar result
without hypnotic side-effects.!>
Areas in the brain associated with particular movement
disorders have been determined by means of cerebral imaging
and autopsies, as well as by animal studies.!7.!S Chorea has been
most consistently associated with lesions in the caudate
nucleus or putamen resulting in disinhibition of the external
globus pallidus. Lesions of the subthalamic internal pallidal
pathway may also result in chorea. The patient in this report
has chorea-type movements in his semi-comatose state that
improve after administration of zolpidem. On the brain SPECT
a bilateral activity increase was noted in the caudate nuclei.
Neurotransmitter abnormalities during chorea include deficient
striatal GABAergic function and striatal cholinergic
interneuron activity and doparninergic hyperactivity in the
nigrostriatal pathway.
Chorea and dystonia may result from hypoxia/ischaemia
owing to global cerebral hypoperfusion or cellular hypoxia
such as occurs in toxic mitochondrial dysfunction. Glutamate is
the main neurotransmitter in the cortical neurons projecting to
the striatum. Hypoxic ischaemic necrosis of the medium-sized
spiny striatal neurons may be responsible for decreased
concentrations of GABA. Global cerebral hypoxia/ischaemia
may cause movement disorders in children and adults. Despite
the global insult, patients often have focal or unilateral findings
clinically and on imaging studiesI' Our patient had evidence of
intracranial bleeding in the midbrain area at the time of his
accident. On his brain SPECT there was a clearly decreased
activity in the left lentiform nucleus that improved after
administration of zolpidem. The basal ganglia receive cortical
input and project back to the frontal cortex through the
thalamus. Together with the circuits originating in the
cerebellum, the basal ganglia-thalamocortical circuit modulates
activity in the corticospinal motor system. In the above patient
there was increased activity in both caudate nuclei and the left
lentiform nucleus. Furthermore, there was a comparative
generalised increase in the neural activity of the cerebrum
compared with the cerebellum after administration of
zolpidem. This was amplified in areas that were hypo-active in




There are two possibilities in terms of interpreting the above
findings. Either ffi.t selective GABA-agonistic action results in
bridging to the conscious state, or the drug has an unknovm
property that results in arousal to consciousness. It causes
increased activity in the cerebrum compared with the
cerebellum, which is selectively amplified in cortical regions
that are hypo-active or hibernating in the semi-comatose state.
These amplified cortical changes may well represent the
'switch on' effect that was observed clinically in this patient.
We are now investigating other patients with similar clinical
conditions.
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